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Furosemide’s one little hydrogen atom:
NMR crystallography structure verification of
powdered molecular organics†
Cory M. Widdifield, Harry Robson and Paul Hodgkinson*
The potential of NMR crystallography to verify molecular crystal
structures deposited in structural databases is evaluated, with two
structures of the pharmaceutical furosemide serving as examples.
While the structures diﬀer in the placement of one H atom, using
this approach, we verify one of the structures in the Cambridge
Structural Database using quantitative tools, while establishing that
the other structure does not meet the verification criteria.
Significant progress has been made in solid-state nuclear
magnetic resonance (SSNMR). With the development of high
applied magnetic fields1 and fast magic-angle spinning (MAS)
probes,2,3 studies of chemical systems that would have been
intractable using SSNMR as recently as 10 years ago are becoming
routine. An area of consistent recent development is ‘NMR
crystallography’.4–6 As the name suggests, it offers insights into
the structures of crystalline materials, but is distinct from
diffraction methods as it uses SSNMR experiments to collect
system data. Alongside the SSNMR advances, developments in
density functional theory (DFT) software operating under periodic
boundary conditions that use pseudopotentials to describe core
electron states and plane waves to describe the valence electrons
have enabled the efficient computation of NMR parameters for
periodic systems.4,7,8 When relativistic effects may be ignored, the
accuracy of these quantum chemical tools is such that, when
paired with SSNMR data, this combined approach has been able
to refine and determine molecular crystal structures in lieu of
diffraction,9–11 although this approach is not yet a general method
for crystal structure determinations.
Diﬀraction-based crystal structure determination methods
have been crucial in the advancement of chemistry.12 Crystal
structure databases, such as the Cambridge Structural Database
(CSD), are important repositories of crystal structures deter-
mined using diﬀraction methods. While metrics are available
to the crystallographic community to quantify the quality of a
crystal structure refinement (e.g., R-factors), systematic studies
of the CSD have shown that a significant portion of deposited
structures possess unrealistic structural features.13–15 Indepen-
dent verification of crystal structures determined using diffrac-
tion methods could be of significant general value. Indeed,
recent work by van de Streek and Neumann has shown that
dispersion-corrected DFT (dc-DFT) offers the potential to verify
crystal structures by observing the changes in the non-H atomic
positions under a full structural relaxation.16 However, due to
the difficulties in locating hydrogen atom positions by X-ray
diffraction (XRD), prior studies have not included them in their
verification procedures.
In principle, new single-crystal XRD (scXRD) experiments
may be performed to confirm a crystal structure, although this
can be a significant challenge for systems that do not readily
form suﬃciently large single crystals. Secondly, the use of XRD
methods to verify XRD structures, e.g. by comparison against
established distributions of interatomic distances, is obviously
cyclical in nature. NMR crystallographymethods can address both
these aspects. As NMR experiments are sensitive local probes of
structure and dynamics, they probe matter in a diﬀerent fashion
than XRD, and do not require single crystal samples. Based upon
the successes of powder NMR crystallography for structure
determinations,2,9–11 refinements17 and distinctions,18,19 NMR
may have an important role in the verification of crystal struc-
tures deposited in chemical structure databases.
As a test case of NMR crystallography methods to verify crystal
structures, we consider furosemide, which is an important
pharmaceutical listed in the World Health Organization’s List
of Essential Medicines.20 Furosemide has therapeutic applica-
tions related to relieving fluid accumulation in the heart, liver
and kidney due to the partial or total failure of these organs,21
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and in treating hypertension.22 Due to its poor bioavailability,
recent studies have focused on the synthesis of furosemide
co-crystals,23–26 but prior SSNMR data are known for pure
furosemide (form 1).24,27 There are several crystal structure
determinations in the CSD for furosemide (ca. 10), which pro-
vides the opportunity to compare and contrast selected structures
using NMR crystallography methods.
We highlight the structures of two determinations of furosemide
(Fig. 1), referred to here using their CSD reference codes,
FURSEM0128 and FURSEM17.29 The diﬀraction measurement
temperatures were similar between both structures (ambient),
and both have relatively low R-factors (6.8% and 5.7%, respec-
tively). This eliminates complicating factors, such as temperature-
dependent polymorphism and obviously poor structures (i.e.,
R-factor 4 10%).30
A review of furosemide structures in the CSD by Karami et al.31
used simulated powder XRD (pXRD) patterns to show that several
deposited structures were essentially the same polymorphic form
(form 1), and were most correctly described by FURSEM01.
In contrast to the two other known polymorphic forms of
furosemide (forms 2 and 3),32 the structure of FURSEM17 is very
similar to FURSEM01, but contains a chemically non-intuitive
hydrogen bonding motif where one of the COOH hydrogen
atoms is directed away from forming an O–H  O dimer. The
refined structures possess very similar unit cell dimensions and
non-H atomic positions (non-H atomic root-mean-squared
difference (RMSD) value of 0.015 Å for 16 overlaid molecules),
with Z0 = 2. As the major difference between these crystal
structures lies in the placement of a single hydrogen atom,
(Fig. 1) the calculated pXRD patterns are nearly identical (ESI†),
and thus pXRD cannot distinguish between these two structures.
In contrast, NMR experiments are expected to be sensitive to this
structural difference, given their local nature. However, it is
unknown if the sensitivity to this single local difference is
sufficient to distinguish between FURSEM01 and FURSEM17
over the total crystal structure.
We obtained powders of furosemide from two sources. The
first was used as-is from Sigma-Aldrich (S-A), with phase purity
verified by pXRD (ESI†). A second sample was obtained by following
the re-crystallisation procedure advocated by the authors who
obtained the structure of FURSEM17 (ReCryst). This yielded a
suﬃciently large single crystal to solve its crystal structure,
which is referred to as FURSEM-NEW.‡
Fast 1H MAS, 13C and 15N cross-polarization (CP)/MAS, and
1H–13C refocused frequency-switched Lee-Goldburg dipolar
heteronuclear correlation (FSLG-HETCOR) SSNMR experiments
were used to achieve a reasonably complete assignment of the
NMR peaks to sites in the furosemide molecules (Fig. 2 and ESI†).
The present assignment is largely consistent with that of
Longhi et al.,27 however the peak at ca. 138 ppm, assigned here
to C–Cl groups, was apparently not observed in the prior account,
leading to a misassignment. By using variable contact time FSLG-
HETCOR experiments (ESI†), and analysing systematic trends in
computed magnetic shielding values from gauge-including pro-
jector augmented-wave density functional theory (GIPAW DFT)
calculations (ESI†),33 we could distinguish between nearly all of
the H and C chemical sites in the two furosemide molecules of
the asymmetric unit. Further 13C–13C correlation experiments
could provide data for a complete assignment, but as the
1H spin–lattice relaxation value (T1) is over 40 s at room
temperature (ESI†), this experiment is not feasible without
13C isotopic enrichment. Signal enhancement methods such
as dynamic nuclear polarization (DNP),34,35 or the addition of
paramagnetic dopants may also prove fruitful.
The assignment facilitates the comparison between experi-
mentally measured isotropic chemical shift values (diso) with
those calculated using GIPAW DFT, quantified through an
RMSD. This contrasts with earlier work where diﬀerences in
H atom positioning could be distinguished by simple qualitative
comparisons of either 1H fast MAS spectra18 or 13C NMR spectra.19
The quantitative ensemble approach presented here has been used
in NMR crystallography structure determinations of organics,9,10
Fig. 1 An overlay of the asymmetric units of FURSEM01 (C atoms in grey)
and FURSEM17 (C atoms in green). H atoms are generally omitted, but a
critical diﬀerence in the carboxyl H atom positioning is shown. Arrow head
points toward the H position of FURSEM17. Fig. 2 Partial 1H–13C refocused dipolar FSLG-HETCOR NMR spectrum
(B0 = 11.7 T, T = 293(1) K; nMAS = 13.24 kHz, contact time = 100 ms) with site
assignments for the furosemide molecule (inset, S-A sample). The top
horizontal axis shows the 13C CP/MAS NMR spectrum, while the left vertical
axis corresponds to the 60 kHz 1H MAS NMR spectrum of the samematerial.
See ESI† for a detailed account of the assignment.
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but has not previously been used to verify hydrogen positioning.
1H RMSD values of 0.33  0.16 ppm, and 13C RMSD values of
1.9  0.4 ppm are ranges typical for valid molecular organic
structures.§ Accordingly, the crystal structures of FURSEM01,
FURSEM17, and FURSEM-NEW were H-optimised, followed by
GIPAW DFT calculations using CASTEP.36–38 The calculated diso
values for 1H and 13C were compared against those measured
experimentally to yield diso RMSD values, Fig. 3(a and b). In
Fig. 3c we compare the calculated 1H NMR spectra (see ESI,† for
calculated vs. experimental correlation plots) for FURSEM01
and FURSEM17 with the experimental spectrum of S-A.
Although there is some disagreement when considering
calculated and experimental diso(
1H) values for the OH sites
in FURSEM01, this is not suﬃcient to invalidate its structure;
as discussed in the ESI,† structure changes of a few pm can
significantly reduce the 1H RMSD value. Importantly, the overall
agreement between the calculated and experimental data is clearly
much better for the structures of FURSEM01 and FURSEM-NEW,
while the calculated values using the FURSEM17 structure are in
poor agreement with experimental values. Further, the diﬀerences
in the computed 1H and 13C RMSD values for the FURSEM01 and
FURSEM17 structures allow them to be distinguished using NMR
crystallography, with a significance of ca. 2s in both 1H and 13C.
For FURSEM01 and FURSEM-NEW however, the diﬀerences
between both the atomic positions (non-H atomic RMSD over
the unit cell = 0.08 Å), and the computed diso values are minor,
especially when noting that FURSEM-NEW was determined at
120 K, while FURSEM01 was determined at room temperature.
As such these two structures cannot be distinguished by NMR
crystallography, although the slightly lower RMSD values for
FURSEM-NEW may reflect the lower temperature at which the
data were acquired.39 Despite following the crystallisation pro-
cedure of the authors of FURSEM17, we do not arrive at the same
crystal structure.
Due to the good agreement between calculation and experiment
for FURSEM01 (RMSD(1H) = 0.46 ppm and RMSD(13C) = 2.01 ppm),
we state that its structure (and that of FURSEM-NEW) is verified
using NMR crystallography; however, we are unable to verify the
structure of FURSEM17, as both associated RMSD values are
quite large (RMSD(1H) = 0.77 ppm and RMSD(13C) = 2.78 ppm,
Fig. 3(a and b)). The largest contributions to the 1H RMSD value
of FURSEM17 (ESI†) are due to the 1H shift value for the COOH
hydrogen from one of the two furosemide molecules (see the
variation in the computed values in the spectra provided in
Fig. 3c). This is consistent with the previously highlighted
structural diﬀerence between FURSEM01 and FURSEM17.
Omitting this datum from the 1H RMSD calculations signifi-
cantly reduces the calculated 1H RMSD value for FURSEM17
(Fig. 3a, red columns).
Being unable to verify a crystal structure using NMR crystallo-
graphy does not infer a structure is incorrect. Similarly, the approach
we outline should complement existing verification methods, and
does not serve as a replacement. We consider additional computa-
tional information to assess the likelihood that FURSEM17 is an
isolable polymorph of furosemide. From the dc-DFT structure
verification method of van de Streek and Neumann,16 FURSEM01
is validated, as its non-H atomic positions, when subjected to a dc-
DFT calculation that optimises the unit cell and all atoms, do not
change significantly (non-H atomic RMSD for one unit cell = 0.093 Å,
where deviations greater than 0.25 Å are considered significant).
From a dc-DFT geometry optimisation, FURSEM17 is found to be
close to a local energy minimum and hence a theoretically viable
furosemide polymorph. However, the non-H atomic RMSD after
optimisation is 0.327 Å over the unit cell, and so FURSEM17 should
be flagged for closer inspection. NMR crystallography provides an
obvious way to perform such an inspection according to the above
dc-DFT protocol.
Finally, the DFT-calculated enthalpies for the fully-optimised
structures of FURSEM01 and FURSEM17 are distinct, with the
Fig. 3 RMSD values for diso(
1H) (a) and diso(
13C) (b) between experimentally
measured diso of S-A and ReCryst with those computed using GIPAW DFT
on the H-optimised structures indicated. Grey bands correspond to RMSD
ranges established using a series of benchmark organics.§ The 1H RMSD is
highly sensitive to the COOH hydrogen atom position, as shown by RMSD
values which include (blue) and do not include (red) this site. (c) compares
calculated (FURSEM01/FURSEM17) and experimental (S-A) 1H NMR spectra.
Red traces in (c) correspond to the carboxyl H atom from each crystallo-
graphically unique furosemide molecule.
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optimised structure of FURSEM17 being ca. 25 kJ mol1 molecule1
above FURSEM01 (ESI†). Based upon recent findings of the crystal
structure prediction (CSP) community,40,41 such a high energy
structure would be very unlikely to occur under typical conditions.
Indeed, this would establish a new record for an energy diﬀerence
between two non-conformational polymorphic forms by amargin of
7 kJ mol1 molecule1.
In conclusion, we have demonstrated the potential value of
NMR crystallography for the verification of crystal structures.
We verify the structure of FURSEM01 via NMR crystallography,
and show that this conclusion is consistent with other methods,
such as energy calculations using dispersion-corrected DFT. How-
ever, for the crystal structure of FURSEM17, the DFT-computed
chemical shift data is inconsistent with NMR experiments, and
hence its structure is not verified. This conclusion is consistent
with current protocols from the CSP community, and also when
using the method of van de Streek and Neumann.16 We are also
able to distinguish between the FURSEM01 and FURSEM17
structures with ca. 2s confidence, which is noteworthy as the
structures are essentially identical save for the position of one
hydrogen atom. While the diﬀraction community has many
available structure verification tools, the ability to ensure the
quality of crystal structures in databases in a way which is
independent of the chosen experimental method is potentially
important, as these structures are often starting points when
screening for new pharmaceuticals, testing computational
methods, and designing new materials. We are refining and
extending this protocol as part of a systematic study on how to
verify crystal structures using NMR crystallography tools.
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